Oral corticosteroids (OCS) remain widely used in uncontrolled severe asthma and frequently exacerbating chronic obstructive pulmonary disease (COPD), but cumulative exposure is associated with dose-dependent cardiovascular, metabolic, skeletal and infectious harm. Type-2 biologics may reduce OCS burden, although their clinical impact across asthma and COPD remains incompletely defined.
